• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biolinq adds $5m to Series A

March 28, 2019 By Fink Densford

Biolinq

Biosensor developer Biolinq said today that it raised $4.8 million as an extension of its Series A financing round.

The San Diego-based company said that the investment in its expanded, oversubscribed Series A round was led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. With the additional funding, Biolinq said it raised a total of $15 million in the round.

“We are impressed with the initial clinical results Biolinq has achieved with their very promising technology. We believe the company is well positioned to set new standards for minimally invasive CGMs and are excited to support Biolinq during this critical phase as they work towards bringing next-gen solutions to market and explore future applications for people living with type 1 diabetes,” JDRF T1D Fund managing director Katie Ellias said in a press release.

Biolinq is developing a minimally invasive wearable sensor is designed to allow patients with diabetes to continuously monitor their blood glucose without having to perform finger sticks for calibration.

The company said that the new financing will support continued growth of the platform and additional clinical studies.

“Our results to date demonstrate our vision to increase access to CGM and further simplify the management of diabetes. 2018 was a landmark year for Biolinq, marked by the successful completion of our first clinical study. This funding round validates our strong clinical results and will continue to advance our technology platform towards commercial feasibility,” CEO Jared Tangney said in a prepared statement.

Filed Under: Business/Financial News, Diabetes, Wall Street Beat Tagged With: biolinq

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS